Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118876 | 0.85 | ABL1 (0.41) | DGAT1HDAC1ABL1BCRCA2 | |
| SCHEMBL10119267 | 0.83 | FDPS (0.42) | CA2CA1KMT2ABRAF | |
| SCHEMBL12518098 | 0.79 | CTSB (0.63) | — | |
| SCHEMBL12518336 | 0.78 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL10118947 | 0.76 | CA2 (0.52) | CA2CA1KMT2A | |
| SCHEMBL10118924 | 0.75 | CA2 (0.49) | CA2KDRCA1KMT2A | |
| SCHEMBL10118974 | 0.75 | ALDH1A1 (0.48) | KMT2ABRAF | |
| SCHEMBL10118995 | 0.71 | SMN1; SMN2 (0.46) | CA2CA1KMT2A | |
| SCHEMBL14314415 | 0.71 | TAS1R3 (0.55) | KMT2A | |
| SCHEMBL14325308 | 0.70 | LONP1 (0.65) | HDAC1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8637453-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| WO-2012004554-A1 | ALDEHYDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011089396-A2 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE. | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | DGAT1 1733/4885HDAC1 169/4885ABL1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.